For over a decade, and as recently as August, FDA has fully evaluated the emerging scientific evidence and repeatedly ...
Barchart on MSN
This Billionaire Investor Is ‘Thrilled’ to Own Kenvue Stock Despite Tylenol Turbulence. Should You Buy KVUE Here?
Kenvue stock is down 28% in 2025 amid controversy surrounding its Tylenol brand, which is linked to autism when used during ...
“For over a decade — and as recently as August — FDA has fully evaluated the emerging scientific evidence and repeatedly ...
Barchart on MSN
Kenvue's Quarterly Earnings Preview: What You Need to Know
New Jersey-based Kenvue Inc. (KVUE) is a consumer health company operating across the Americas, Europe, EMEA, and the ...
Kenvue, the maker of Tylenol, is urging U.S. health regulators not to add an autism warning label to it and other ...
Bessent calls $20 billion lifeline to Argentina a ‘mission-critical’ function of Treasury during shutdown ...
Kenvue, the maker of Tylenol, opposes proposed changes to the product's safety label regarding potential links to autism and ...
In today’s Pharmaceutical Executive Daily, we cover major leadership changes at Novo Nordisk, Kenvue’s request for the FDA to ...
Perimenopausal women who used estrogen for at least 10 years before their periods stopped had 60% lower odds for breast ...
Johnson & Johnson stopped selling its talc-based baby powder in the US and Canada in 2020. In 2023, it switched to a cornstarch formula. The company maintains its baby powder is safe. Its consumer ...
Tylenol's maker, Kenvue, has strongly opposed a proposed change to the product's safety label, following research suggesting ...
The big news of the month is that Kering and L’Oreal have made an alliance in which Kering is selling its beauty division to L’Oreal. Kering has some major debt to sort out somewhat urgently which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback